Ericka P. Simpson, MD

The Sumner Family Chair in Neuromuscular Research, Stanley H. Appel Department of Neurology
Associate Professor of Clinical Neurology, Institute for Academic Medicine
Associate Clinical Member, Research Institute
Program Director, Neurology Residency and Neuromuscular Medicine Residency, Stanley H. Appel Department of Neurology
Houston Methodist
Weill Cornell Medical College


Research Lab


Biography

While completing her postdoctoral training, Dr. Simpson studied under the renowned Dr. Stanley Appel, the current chair of the Department of Neurology at Houston Methodist Hospital and the founder of the Houston Methodist Neurological Institute. After completion of a fellowship in Dr. Appel’s laboratory, she became a tenure track Associate Professor of Neurology at the Baylor College of Medicine in Houston, Texas. Dr. Simpson is a member of the American Academy of Neurology, the American Board of Psychiatry and Neurology, and a recipient of the Robert Wood Johnson Foundation’s Minority Medical Faculty Development Program. She joined the Houston Methodist Specialty Physician Group in 2005.

Description of Research

Dr. Simpson’s research aims to characterize the peripheral immune inflammatory response in ALS and other neurodegenerative diseases, and identify the potential markers that may reflect disease activity and progression. Her translational research seeks to identify and develop effective therapies that positively alter the natural progression of these diseases, including Myotonic Dystrophy, myasthenia gravis, and chronic inflammatory polyneuropathies. 

Areas Of Expertise

Stem cells ALS Neurology Biomarkers Dendritic cells MCP-1 Microglia
Education & Training

Residency, Baylor College of Medicine
Internship, Baylor College of Medicine
MD, University of Texas Medical Branch at Galveston
Research Fellowship, Baylor College of Medicine
Publications

Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis
Thonhoff, JR, Simpson, EP & Appel, SH 2018, Current Opinion in Neurology. DOI: 10.1097/WCO.0000000000000599

Expanded autologous regulatory T-lymphocyte infusions in ALS A phase I, first-in-human study
Thonhoff, JR, Beers, DR, Zhao, W, Pleitez, M, Simpson, EP, Berry, JD, Cudkowicz, ME & Appel, SH 2018, Neurology: Neuroimmunology and NeuroInflammation, vol. 5, no. 4, e465. DOI: 10.1212/NXI.0000000000000465

Expanded autologous regulatory T-lymphocyte infusions in ALS
Thonhoff, JR, Beers, DR, Zhao, W, Pleitez, M, Simpson, EP, Berry, JD, Cudkowicz, ME & Appel, SH 2018, Neurology - Neuroimmunology Neuroinflammation, vol. 5, no. 4.

Intravenous versus subcutaneous immunoglobulin – Authors' reply
PATH study group 2018, The Lancet Neurology, vol. 17, no. 5, pp. 393-394. DOI: 10.1016/S1474-4422(18)30109-1

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene
ITALSGEN Consortium, Genomic Translation for ALS Care (GTAC) Consortium, ALS Sequencing Consortium, NYGC ALS Consortium, Answer ALS Foundation, Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium, SLAGEN Consortium, French ALS Consortium & Project MinE ALS Sequencing Consortium 2018, Neuron, vol. 97, no. 6, pp. 1268-1283.e6. DOI: 10.1016/j.neuron.2018.02.027

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial
PATH study group & PATH study group 2018, The Lancet Neurology, vol. 17, no. 1, pp. 35-46. DOI: 10.1016/S1474-4422(17)30378-2

Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability
Berry, JD, Paganoni, S, Atassi, N, Macklin, EA, Goyal, N, Rivner, M, Simpson, E, Appel, S, Grasso, DL, Mejia, NI, Mateen, F, Gill, A, Vieira, F, Tassinari, V & Perrin, S 2017, Muscle and Nerve, vol. 56, no. 6, pp. 1077-1084. DOI: 10.1002/mus.25733

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
REGAIN Study Group 2017, The Lancet Neurology, vol. 16, no. 12, pp. 976-986. DOI: 10.1016/S1474-4422(17)30369-1

Neurogenic Orthostatic Hypotension: An Iatrogenic Complication of Successful Pancreas Transplantation?
Kuten, SA, Simpson, EP, Gaber, AO, Nguyen, DTM, Graviss, EA, Patel, S & Knight, RJ 2017, .

Improving symptom management for people with amyotrophic lateral sclerosis
Nicholson, K, Murphy, A, Mcdonnell, E, Shapiro, J, Simpson, E, Glass, J, Mitsumoto, H, Forshew, D, Miller, R & Atassi, N 2017, Muscle and Nerve. DOI: 10.1002/mus.25712

A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis
Pasnoor, M, He, J, Herbelin, L, Burns, TM, Nations, S, Bril, V, Wang, AK, Elsheikh, BH, Kissel, JT, Saperstein, D, Shaibani, JA, Jackson, C, Swenson, A, Howard, JF, Goyal, N, David, W, Wicklund, M, Pulley, M, Becker, M, Mozaffar, T, Benatar, M, Pazcuzzi, R, Simpson, E, Rosenfeld, J, Dimachkie, MM, Statland, JM & Barohn, RJ 2016, Neurology, vol. 87, no. 1, pp. 57-64. DOI: 10.1212/WNL.0000000000002795

Myelopathies
Eatman, J & Simpson, EP 2016, . in Neurology Secrets: Sixth Edition. Elsevier Inc. pp. 103-113. DOI: 10.1016/B978-0-323-35948-1.00008-5

Neurologic complications of systemic disease
Eatman, JD & Simpson, EP 2016, . in Neurology Secrets: Sixth Edition. Elsevier Inc. pp. 336-352. DOI: 10.1016/B978-0-323-35948-1.00024-3

Amyotrophic lateral sclerosis
Simpson, EP & Appel, SH 2016, . in Neuroimmune Pharmacology. Springer International Publishing, pp. 493-502. DOI: 10.1007/978-3-319-44022-4_32

A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement
Macchi, Z, Wang, Y, Moore, D, Katz, J, Saperstein, D, Walk, D, Simpson, E, Genge, A, Bertorini, T, Fernandes, JA, Swenson, A, Elman, L, Dimachkie, M, Herbelin, L, Miller, J, Lu, J, Wilkins, H, Swerdlow, RH, Statland, J & Barohn, R 2015, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, vol. 16, no. 5-6, pp. 345-352. DOI: 10.3109/21678421.2015.1026826

Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways
Cirulli, ET, Lasseigne, BN, Petrovski, S, Sapp, PC, Dion, PA, Leblond, CS, Couthouis, J, Lu, Y-F, Wang, Q, Krueger, BJ, Ren, Z, Keebler, J, Han, Y, Levy, SE, Boone, BE, Wimbish, JR, Waite, LL, Jones, AL, Carulli, JP, Day-Williams, AG, Staropoli, JF, Xin, WW, Chesi, A, Raphael, AR, McKenna-Yasek, D, Cady, J, Vianney de Jong, JMB, Kenna, KP, Smith, BN, Topp, S, Miller, J, Gkazi, A, Al-Chalabi, A, van den Berg, LH, Veldink, J, Silani, V, Ticozzi, N, Shaw, CE, Baloh, RH, Appel, S, Simpson, E, Lagier-Tourenne, C, Pulst, SM, Gibson, S, Trojanowski, JQ, Elman, L, McCluskey, L, Grossman, M, Shneider, NA, Chung, WK & FALS Sequencing Consortium 2015, Science (New York, N.Y.), vol. 347, no. 6229, pp. 1436-41. DOI: 10.1126/science.aaa3650

Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: A multi-stage, randomised, double-blind, placebo-controlled trial
Cudkowicz, ME, Titus, S, Kearney, M, Yu, H, Sherman, A, Schoenfeld, D, Hayden, D, Shui, A, Brooks, B, Conwit, R, Felsenstein, D, Greenblatt, DJ, Keroack, M, Kissel, JT, Miller, R, Rosenfeld, J, Rothstein, JD, Simpson, E, Tolkoff-Rubin, N, Zinman, L, Shefner, JM, Kalra, S, Korngut, L, Omar-Crawford, H, Sekhon, R, White, C, Benstead, T, Grant, I, Reidy, S, McIntosh, C, McKinley, J, Shoesmith, C, Zinman, L, Botez, S, Bouchard, JP, DAmour, M, Genge, A, Hank, N, Levine, T, Saperstein, D, Alvarez, R, Banda, C, Garcia, R, Graves, M, Gruendler, H, Katz, J, Lin, F, Lomen-Hoerth, C, Martin, V, Miller, R, Moses, D, Mozaffar, T, Nist, L, Oskarsson, B, Rosenfeld, J, Tsimerinov, E, Tully, P, Villierme, C, Voelz, K, Wiedau-Pazos, M, Rollins, Y, Felice, K, Bayat, E, Kelly, AN, Boylan, KB, DeSaro, P, Koggan, D, Verma, A, Bordeau, J, Glass, J, Polak, M, Quarles, B, Rivner, MH, Casey, P, Sufit, R, Bodkin, C, Guingrich, S, Kincaid, J, Micheels, A, Pascuzzi, R, Snook, R, Barohn, RJ, Dick, A, Herbelin, L, Dimachkie, MM, McVey, AL, Walsh, M, Wang, Y, Hutchison, J, Kasarskis, E, King, J, Tandy, T, Thomas, S, Vanderpool, K, Rothstein, J, Andres, P, Bellanich, M, Cudkowicz, ME, David, W, Goldenberg, A, Greenblatt, DJ, Krivickas, L, Loci, L, Majkut, M, OConnor, O, Parkinson, M, Pulley, D, Russell, J, Sullivan, L, Foley, H, Gelinas, D, Newman, DS, Bundlie, S, Leviton, T, Patel, S, Rohde, C, Swanson, S, Tiryaki, E, Fann, A, Hayat, G, Pestronk, A, Pattee, GL, Weber, B, Keroack, M, Belsh, B, Belsh, J, Mertz, MA, DeNero, AM, Imperato, T, Lange, DJ, Kassebaum, N, MacGowan, D, Mitsumoto, H, Scelsa, SN, Shahbazi, M, Shefner, JM, Simionescu, L, Watson, ML, Wymer, J, Bravver, E, Brooks, BR, Caress, J, Cartwright, MS, Johnston-Crews, T, Lary, C, Shuh, J, Bartlett, A, Berry, N, Kissel, JT, Kuenzler, R, Pioro, EP, Quick, A, Ash, B, Goslin, K, Deboo, A, Giampole, A, Heiman-Patterson, T, Lacomis, D, McCluskey, L, Powell, M, Rana, S, Rojas, L, Rowlands, D, Simmons, Z, Stephens, HE, DeCandio, M, Stickler, D, Davis, DL, Donofrio, PD, Halton, S, Hand, S, Hastings, M, Heitzman, D, Lay, L, McCloskey, J, Simpson, E, Bromberg, M, Joshi, A & Phillips, LH 2014, The Lancet Neurology, vol. 13, no. 11, pp. 1083-1091. DOI: 10.1016/S1474-4422(14)70222-4

TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis
Cady, J, Koval, ED, Benitez, BA, Zaidman, C, Jockel-Balsarotti, J, Allred, P, Baloh, RH, Ravits, J, Simpson, E, Appel, SH, Pestronk, A, Goate, AM, Miller, TM, Cruchaga, C & Harms, MB 2014, JAMA Neurology, vol. 71, no. 4, pp. 449-453. DOI: 10.1001/jamaneurol.2013.6237

Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled phase 2 trial
Wills, AM, Hubbard, J, Macklin, EA, Glass, J, Tandan, R, Simpson, EP, Brooks, B, Gelinas, D, Mitsumoto, H, Mozaffar, T, Hanes, GP, Ladha, SS, Heiman-Patterson, T, Katz, J, Lou, JS, Mahoney, K, Grasso, D, Lawson, R, Yu, H & Cudkowicz, M 2014, The Lancet, vol. 383, no. 9934, pp. 2065-2072. DOI: 10.1016/S0140-6736(14)60222-1

Correction to: 'Seeking a measure of clinically meaningful change in ALS'
McElhiney, M, Rabkin, JG, Goetz, R, Katz, J, Miller, RG, Forshew, DA, David, W, Cudkowicz, M, Glass, JD, Appel, S, Simpson, E & Mitsumoto, H 2014, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, vol. 15, no. 7-8. DOI: 10.3109/21678421.2014.964589